54 42

Cited 9 times in

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.

Authors
 Michael F. Press  ;  Catherine E. Ellis  ;  Robert C. Gagnon  ;  Tobias J. Grob  ;  Marc Buyse  ;  Ivonne Villalobos  ;  Zhiyong Liang  ;  Shafei Wu  ;  Yung-Jue Bang  ;  Shu-Kui Qin  ;  Hyun Cheol  ;  Chung  ;  Jianming Xu  ;  Joon Oh Park  ;  Krzysztof Jeziorski  ;  Karen Afenjar  ;  Yanling Ma  ;  Monica C. Estrada  ;  Douglas M. Robinson  ;  Stefan J. Scherer  ;  Guido Sauter  ;  J. Randolph Hecht  ;  Dennis J. Slamon 
Citation
 Molecular Cancer Therapeutics, Vol.16(1) : 228-238, 2017 
Journal Title
 Molecular Cancer Therapeutics 
ISSN
 1535-7163 
Issue Date
2017
MeSH
Adenocarcinoma/drug therapy ; Adenocarcinoma/metabolism ; Adenocarcinoma/mortality ; Adult ; Aged ; Aged, 80 and over ; Esophageal Neoplasms/drug therapy ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/metabolism ; Esophageal Neoplasms/mortality ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Male ; Middle Aged ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/therapeutic use ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/genetics ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/mortality ; Treatment Outcome ; Young Adult
Abstract
HER2/ERBB2 status is used to select patients for HER2-targeted therapy. HER2/ERBB2 amplification/overexpression of upper gastrointestinal (UGI) adenocarcinomas was determined locally or in two central laboratories to select patients for the TRIO-013/LOGiC trial of chemotherapy with or without lapatinib. Patients selected locally had central laboratory confirmation of HER2 amplification for inclusion in the primary efficacy population. HER2 was assessed with PathVysion or IQ PharmDx FISH and HercepTest immunohistochemistry assays. Associations with outcomes were retrospectively evaluated. Overall, HER2 status was determined in UGI cancers from 4,674 patients in a central laboratory for eligibility (1,995 cases) and for confirmation of local HER2 results (333 cases). Of 1,995 adenocarcinomas screened centrally, 322 (16.1%) had HER2-amplified disease with 29 (1.5%) showing HER2 genomic heterogeneity. Men and older patients had higher rates of amplification. Of 545 patients accrued to the trial (gastric, 87.3%; GEJ, 8.3% and esophageal cancer, 4.4%), 487 patients (89%) were centrally confirmed as having HER2-amplified disease. Concordance between central and local HER2 testing was 83%. Concordance between PathVysion and IQ PharmDx FISH assays was 99% and FISH in the two central laboratories was 95%. Lapatinib-treated Asian participants and those less than 60 years had significant improvement in progression-free survival (PFS), particularly among those whose cancers had 5.01-10.0 and >10.0-fold amplification of HER2 In conclusion, HER2 is commonly amplified in UGI adenocarcinomas with amplification highly correlated to overexpression, and HER2 amplification levels correlated with PFS. While HER2 genomic heterogeneity occurs, its prevalence is low. Mol Cancer Ther; 16(1); 228-38.
Files in This Item:
T201703329.pdf Download
DOI
10.1158/1535-7163.MCT-15-0887
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
정현철(Chung, Hyun Cheol) ORCID logo https://orcid.org/0000-0002-0920-9471
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160796
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse